The Cholinergic System and Cognitive Enhancement: Alpha-GPC, Citicoline, and Choline Science (2026)

1. The Cholinergic System: An Overview

The cholinergic system is one of the most extensively studied neurotransmitter systems in neuroscience. Named after acetylcholine (ACh), the first neurotransmitter ever identified, this system plays a foundational role in cognitive processes including memory encoding, sustained attention, and synaptic plasticity. For researchers exploring cholinergic nootropics, a thorough understanding of the underlying neurobiology is essential before evaluating individual compounds.

Acetylcholine Synthesis and Degradation

Acetylcholine is synthesized in cholinergic neurons through a single-step reaction catalysed by the enzyme choline acetyltransferase (ChAT). This enzyme combines choline, an essential nutrient obtained primarily through diet, with acetyl-CoA, a metabolic intermediate derived from glucose metabolism. The reaction occurs in the cytoplasm of the presynaptic terminal, and the resulting acetylcholine is packaged into synaptic vesicles by the vesicular acetylcholine transporter (VAChT).

Upon neuronal depolarisation, acetylcholine is released into the synaptic cleft, where it binds to postsynaptic receptors. The signal is rapidly terminated by acetylcholinesterase (AChE), an enzyme that hydrolyses acetylcholine back into choline and acetate. The liberated choline is then recaptured by the presynaptic neuron through high-affinity choline transporters, making choline availability a rate-limiting factor in sustained acetylcholine production (Hasselmo, 2006).

Muscarinic and Nicotinic Receptors

Acetylcholine acts on two major receptor families. Muscarinic receptors (M1 through M5) are G-protein-coupled receptors found throughout the central nervous system. The M1 subtype is particularly relevant to cognition, as it is densely expressed in the hippocampus and cortex. M1 receptor activation facilitates long-term potentiation (LTP) and is associated with improved memory consolidation.

Nicotinic receptors are ligand-gated ion channels that mediate fast synaptic transmission. The alpha-7 (α7) and alpha-4-beta-2 (α4β2) subtypes are the most studied in the context of cognition. Alpha-7 receptors are concentrated in the hippocampus and prefrontal cortex and are implicated in attentional processing and working memory. Both receptor families represent targets for pharmacological intervention in cognitive disorders.

Cholinergic Pathways in the Brain

The principal cholinergic projection system relevant to cognition originates in the basal forebrain, particularly the nucleus basalis of Meynert (NBM) and the medial septum. The NBM provides diffuse cholinergic innervation to the cerebral cortex, while the medial septum projects to the hippocampus via the septohippocampal pathway. These projections modulate cortical arousal, attentional gating, and memory encoding. The degeneration of these pathways is a hallmark of Alzheimer’s disease and forms the basis of the cholinergic hypothesis of dementia.

2. How Acetylcholine Supports Cognition

The relationship between acetylcholine and cognitive function has been investigated for over five decades. The evidence consistently demonstrates that cholinergic signalling is not merely correlated with cognitive performance but is mechanistically required for several core cognitive processes.

Long-Term Potentiation and Memory

Long-term potentiation, the synaptic mechanism widely regarded as the cellular basis of learning and memory, is strongly modulated by acetylcholine. In the hippocampus, acetylcholine enhances LTP induction by activating M1 muscarinic receptors, which in turn modulate NMDA receptor function. Hasselmo’s influential 2006 review demonstrated that cholinergic input to the hippocampus shifts the network from a retrieval mode to an encoding mode, facilitating the formation of new memories while suppressing interference from previously stored information (Hasselmo, 2006).

Attention and Executive Function

Cholinergic projections from the basal forebrain to the prefrontal cortex are critical for sustained attention and executive function. Lesion studies and pharmacological blockade of cholinergic transmission consistently produce deficits in attentional tasks. Conversely, enhancement of cholinergic tone, whether through acetylcholinesterase inhibitors or precursor loading, tends to improve performance on tasks requiring vigilance and selective attention (Sarter et al., 2005).

The Cholinergic Hypothesis of Alzheimer’s Disease

The observation that Alzheimer’s disease involves early and severe degeneration of basal forebrain cholinergic neurons led to the cholinergic hypothesis, which proposes that cognitive decline in Alzheimer’s is substantially driven by cholinergic deficit. This hypothesis motivated the development of acetylcholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, which remain first-line pharmacotherapy for mild to moderate Alzheimer’s disease. While the hypothesis has been refined over the decades to incorporate amyloid and tau pathology, the cholinergic component remains clinically relevant (Francis et al., 1999).

3. Choline: The Essential Precursor

Choline was officially recognised as an essential nutrient by the Institute of Medicine in 1998. It serves as the direct precursor to acetylcholine and is also required for the synthesis of phosphatidylcholine, a major component of cell membranes. Adequate choline intake is therefore necessary not only for neurotransmitter production but also for structural brain integrity.

Dietary Sources and Recommended Intake

The adequate intake (AI) for choline is 550 mg per day for adult males and 425 mg per day for adult females. Rich dietary sources include eggs (one large egg contains approximately 147 mg of choline), liver, beef, fish, and soybeans. Despite the availability of these sources, population-level data consistently shows that the majority of adults do not meet the adequate intake through diet alone (Zeisel, 2006).

Prevalence of Deficiency

Data from the National Health and Nutrition Examination Survey (NHANES) indicate that approximately 90% of the population consumes less than the adequate intake of choline. This is particularly concerning for populations with increased demands, including pregnant and lactating women, endurance athletes, and individuals using compounds that increase acetylcholine turnover. Choline deficiency has been associated with liver dysfunction, muscle damage, and impaired cognitive performance (Zeisel, 2006). A future article on choline deficiency will explore these consequences in greater detail.

Why Supplementation Matters for Researchers

For researchers investigating cholinergic nootropics, choline supplementation serves a dual purpose. First, it addresses the baseline dietary shortfall that is nearly universal in Western populations. Second, and more relevant to nootropic protocols, supplemental choline provides the substrate necessary to support increased acetylcholine synthesis when cholinergic demand is elevated by other compounds, most notably the racetam family. The form of choline supplementation matters considerably, as bioavailability and ability to cross the blood-brain barrier vary substantially between compounds.

4. Alpha-GPC (L-Alpha Glycerylphosphorylcholine): Research and Evidence

Alpha-GPC is a choline compound that occurs naturally in the brain as a byproduct of phosphatidylcholine metabolism. It is one of the most bioavailable forms of supplemental choline and has been the subject of extensive clinical investigation, particularly in Europe, where it has been used as a prescription medication for cognitive disorders. Researchers interested in the best choline supplements for cognitive protocols frequently identify Alpha-GPC as a leading candidate. Our Alpha-GPC guide expands on the evidence presented here.

Mechanism of Action

Alpha-GPC is water-soluble and readily crosses the blood-brain barrier. Once in the central nervous system, it is deacetylated to release free choline, which is then available for acetylcholine synthesis via ChAT. Alpha-GPC delivers approximately 40% choline by weight, the highest percentage of any commercially available choline supplement. In addition to serving as a choline donor, Alpha-GPC may support phosphatidylcholine synthesis in neuronal membranes, contributing to membrane fluidity and structural integrity (Traini et al., 2013).

Clinical Evidence

A comprehensive review by Traini et al. (2013) evaluated the clinical literature on Alpha-GPC in cognitive disorders. Across multiple trials involving patients with Alzheimer’s disease and vascular dementia, Alpha-GPC at doses of 1200 mg per day consistently produced statistically significant improvements on standardised cognitive assessments including the ADAS-Cog and MMSE scales. The effects were observed as early as 90 days and persisted through 180-day follow-up periods.

In healthy populations, the evidence is more limited but nonetheless suggestive. A study by Parker et al. (2015) examined the effects of Alpha-GPC on physical and cognitive performance in young adults, finding that 600 mg of Alpha-GPC significantly increased growth hormone secretion and peak force production compared to placebo. While this study was primarily focused on athletic performance, the growth hormone findings have implications for neuroprotection and neural repair processes (Parker et al., 2015).

Dosing in Research Contexts

Clinical trials have typically used doses between 400 mg and 1200 mg per day, divided into two or three administrations. The most common research dose for cognitive applications is 300 to 600 mg taken one to two times daily. When used as part of a racetam stack, doses tend to cluster around 300 mg per racetam dose.

5. Citicoline (CDP-Choline): Research and Evidence

Citicoline, also known as cytidine-5′-diphosphocholine (CDP-choline), is a naturally occurring intermediate in the synthesis of phosphatidylcholine. It is unique among choline supplements in that it provides both choline and cytidine, the latter of which is converted to uridine in the body. This dual pathway gives Citicoline a broader mechanism of action compared to other choline sources. A dedicated Citicoline deep dive and an Alpha-GPC vs Citicoline comparison article will be published as companion pieces to this pillar post.

Mechanism of Action

Following oral administration, Citicoline is hydrolysed in the gut into choline and cytidine, both of which are absorbed and cross the blood-brain barrier independently. In the brain, choline is incorporated into acetylcholine via ChAT and into phosphatidylcholine via the Kennedy pathway. Cytidine is converted to uridine, which participates in RNA synthesis and, importantly, stimulates the P2Y receptor pathway involved in neurite outgrowth and synaptogenesis. This dual mechanism positions Citicoline as both a cholinergic enhancer and a broader neuroprotective agent (Secades and Lorenzo, 2006).

Clinical Evidence

The Cochrane review by Fioravanti and Yanagi (2005) evaluated 14 randomised controlled trials of Citicoline in patients with cognitive and behavioural disturbances associated with chronic cerebrovascular disease. The analysis found consistent positive effects on memory, attention, and behaviour across studies, with Citicoline at doses of 500 to 2000 mg per day. The review concluded that while the evidence was promising, larger and more methodologically rigorous trials were needed.

Citicoline has been extensively studied in stroke recovery. A pooled analysis of stroke trials demonstrated that Citicoline administration within 24 hours of ischaemic stroke onset improved functional outcomes at 3 months. The neuroprotective effects are attributed to Citicoline’s ability to stabilise neuronal membranes, reduce free fatty acid release during ischaemia, and support phospholipid resynthesis in damaged tissue (Davalos et al., 2002).

Dosing in Research Contexts

Research doses range from 250 mg to 2000 mg per day. For general cognitive support, 250 to 500 mg per day is typical. Stroke recovery trials have used 500 to 2000 mg per day. Citicoline delivers approximately 18% choline by weight, less than Alpha-GPC, but its additional uridine pathway compensates through complementary neuroprotective mechanisms.

6. Other Choline Sources: Choline Bitartrate, Phosphatidylcholine, DMAE

While Alpha-GPC and Citicoline dominate the research literature on cholinergic nootropics, several other choline-related compounds are commercially available. Understanding their limitations helps researchers make informed decisions about supplementation protocols.

Choline Bitartrate

Choline bitartrate is the most affordable and widely available form of supplemental choline. It delivers approximately 41% choline by weight, comparable to Alpha-GPC. However, choline bitartrate has poor blood-brain barrier penetration, meaning that while it effectively raises plasma choline levels, its impact on central acetylcholine synthesis is limited. It may serve adequately for addressing peripheral choline deficiency, such as supporting liver function, but it is generally considered insufficient for cognitive enhancement protocols.

Phosphatidylcholine

Phosphatidylcholine is the predominant phospholipid in cell membranes and a natural dietary source of choline. It delivers only about 13% choline by weight. While phosphatidylcholine supplementation supports membrane health, its low choline yield per gram and modest blood-brain barrier penetration make it a poor choice as a primary cholinergic nootropic. It is better understood as a structural lipid supplement than a cognitive enhancer.

DMAE (Dimethylaminoethanol)

DMAE is structurally related to choline and has been marketed as a cognitive enhancer for decades. However, the evidence base for DMAE is considerably weaker than for Alpha-GPC or Citicoline. DMAE does cross the blood-brain barrier, but its conversion to choline in the brain is inefficient. Some evidence suggests that DMAE may actually inhibit choline uptake by competing for the same transporters. Most researchers in the nootropic community have moved away from DMAE in favour of Alpha-GPC or Citicoline.

7. Choline Source Comparison Table

Compound	Bioavailability	Choline Content (per gram)	Crosses BBB	Additional Benefits	Typical Dose	Relative Cost
Alpha-GPC	High	~400 mg (40%)	Yes	GH secretion, membrane support	300-1200 mg/day	Moderate-High
Citicoline (CDP-Choline)	High	~180 mg (18%)	Yes (as choline + cytidine)	Uridine pathway, neuroprotection, membrane repair	250-2000 mg/day	Moderate-High
Choline Bitartrate	Moderate (peripheral)	~410 mg (41%)	Poorly	Liver support	500-2000 mg/day	Low
Phosphatidylcholine	Low-Moderate	~130 mg (13%)	Poorly	Membrane structural support	1200-3600 mg/day	Low-Moderate
DMAE	Moderate	N/A (indirect precursor)	Yes	Antioxidant (limited data)	100-300 mg/day	Low

For researchers seeking the most effective cholinergic nootropics, Alpha-GPC and Citicoline represent the evidence-backed choices. The selection between them depends on the specific goals of the research protocol, which is discussed further in the “Choosing the Right Choline Source” section below. See our guides to Alpha-GPC and CDP-Choline for detailed compound analyses.

8. The Racetam-Choline Synergy

One of the most well-established principles in nootropic research is the synergistic relationship between racetam compounds and choline supplementation. This synergy is grounded in the pharmacological mechanism of the racetam class and the metabolic demands that these compounds place on the cholinergic system. Researchers who are new to this relationship will benefit from reviewing our detailed guide on piracetam research, evidence, and safety.

Why Racetams Increase Cholinergic Demand

Racetams, including piracetam and aniracetam, enhance cognitive function in part by increasing the firing rate of cholinergic neurons and enhancing acetylcholine receptor sensitivity. This increased cholinergic activity leads to greater acetylcholine turnover, meaning that more acetylcholine is being synthesised, released, and degraded per unit of time. When the supply of free choline is insufficient to keep pace with this elevated demand, acetylcholine levels can actually decline below baseline. A dedicated article explaining why every racetam stack needs choline will provide further detail on this phenomenon.

The Racetam Headache Phenomenon

The most commonly reported side effect of racetam use, particularly with piracetam, is headache. The prevailing explanation in the research community is that racetam-induced acceleration of acetylcholine turnover depletes presynaptic choline stores faster than they can be replenished through diet alone. The resulting transient acetylcholine deficit manifests as headache. Co-administration of a bioavailable choline source, typically Alpha-GPC or Citicoline, reliably prevents or resolves this side effect in the majority of cases.

Optimal Stacking Ratios

While no single ratio has been established through randomised controlled trials, the research community has converged on practical guidelines based on clinical observation and mechanistic reasoning. For piracetam (typically dosed at 1600 to 4800 mg per day), a common recommendation is 300 mg of Alpha-GPC or 250 mg of Citicoline per 1600 mg dose of piracetam. For more potent racetams such as aniracetam or oxiracetam, which produce stronger cholinergic effects at lower doses, proportionally more choline relative to racetam dose may be warranted. Researchers should note that these ratios represent community consensus rather than clinical trial data, and individual variation in choline metabolism may necessitate adjustment.

9. Choline for Non-Racetam Users

The benefits of choline supplementation extend well beyond the racetam stacking context. Researchers investigating standalone cognitive enhancement, liver health, or developmental neurobiology will find that choline merits attention on its own terms.

Standalone Cognitive Benefits

Clinical trials of both Alpha-GPC and Citicoline in elderly populations with cognitive decline have demonstrated improvements in memory and attention independent of any co-administered compounds. The mechanisms include direct support of acetylcholine synthesis, enhanced phospholipid membrane turnover, and, in the case of Citicoline, uridine-mediated support of synaptic function. For individuals who are not using racetams but wish to support cholinergic function, either compound represents a rational choice.

Liver Health

Choline is essential for very-low-density lipoprotein (VLDL) assembly in the liver. Without adequate choline, the liver cannot export triglycerides efficiently, leading to hepatic fat accumulation. Choline deficiency is a recognised risk factor for non-alcoholic fatty liver disease (NAFLD). While Alpha-GPC and Citicoline are typically chosen for their central nervous system effects, they also contribute to hepatic choline pools and may support liver health as a secondary benefit.

Pregnancy and Fetal Development

Choline requirements increase substantially during pregnancy, as the nutrient is critical for fetal brain development, neural tube closure, and hippocampal neurogenesis. Zeisel’s landmark 2006 review established that maternal choline intake during pregnancy influences offspring cognitive function, with higher intakes associated with improved memory performance in animal models (Zeisel, 2006). Adequate choline during pregnancy is also associated with reduced risk of neural tube defects. Pregnant or nursing women should consult a healthcare provider regarding appropriate supplementation. A detailed article on choline deficiency and its systemic consequences is in development.

10. Safety, Side Effects, and Contraindications

Cholinergic nootropics are generally well tolerated across the dosing ranges used in clinical research. However, researchers should be aware of potential adverse effects and contraindications.

Common Side Effects

The most frequently reported side effects of choline supplementation include gastrointestinal discomfort (nausea, diarrhoea, abdominal cramping), headache, and insomnia when taken late in the day. These effects are typically dose-dependent and resolve with dose reduction. At very high doses (above 3500 mg of elemental choline per day), a fishy body odour may develop due to excessive trimethylamine production.

Cholinergic Excess

Overconsumption of cholinergic compounds can lead to a state of cholinergic excess, characterised by depressed mood, excessive salivation, muscle tension, and gastrointestinal distress. This is the opposite problem from choline depletion and serves as a reminder that more is not always better. Researchers should titrate doses carefully, beginning at the lower end of the recommended range and increasing only as needed.

Contraindications

Individuals with a history of depression, particularly bipolar disorder, should exercise caution with cholinergic compounds, as elevated acetylcholine has been associated with depressive symptomatology in some models. Alpha-GPC should be used cautiously by individuals taking anticholinergic medications, as the effects may counteract one another. Citicoline’s dopaminergic properties warrant caution in individuals with a history of psychosis or those taking antipsychotic medications. As with all research compounds, consultation with a qualified healthcare professional is advised before initiation.

11. Regulatory Status in Canada

In Canada, choline supplements occupy a regulatory category that differs from both prescription medications and unregulated substances. Health Canada classifies choline, Alpha-GPC, and Citicoline as natural health products (NHPs) when marketed with health claims. Products making specific therapeutic claims require a Natural Product Number (NPN). When sold as research compounds without therapeutic claims, they fall outside the NHP framework.

Researchers in Canada should be aware that while choline compounds are legally available for purchase, the regulatory environment is distinct from the United States, where dietary supplements are regulated under DSHEA. In Canada, the evidence requirements for NPN approval are more stringent. Alpha-GPC and Citicoline are not prescription medications in Canada, but they are also not classified as standard food ingredients. Researchers should verify the regulatory status of any compound they intend to use and ensure compliance with applicable federal and provincial regulations.

12. Choosing the Right Choline Source

Selecting the appropriate choline source depends on the specific objectives of the research protocol, budget considerations, and whether the choline will be used as a standalone compound or as part of a broader nootropic stack.

For researchers whose primary goal is to support acetylcholine synthesis in conjunction with a racetam protocol, Alpha-GPC is often the preferred choice. Its high choline content per gram (40%) and established blood-brain barrier penetration make it the most direct route to elevating central choline availability. It is the logical default for those building a racetam-choline stack.

For researchers seeking broader neuroprotective effects beyond acetylcholine support, Citicoline offers a compelling advantage. The uridine pathway provides additional mechanisms of action, including support for phospholipid synthesis and synaptic plasticity, that Alpha-GPC does not offer. Citicoline may be preferred in protocols targeting age-related cognitive decline, post-stroke recovery research, or any context where membrane repair is a priority.

For researchers on a constrained budget who require only peripheral choline repletion (for example, supporting liver function or meeting basic nutritional requirements), choline bitartrate provides adequate elemental choline at the lowest cost. It should not, however, be relied upon as the sole choline source in cognitive enhancement protocols due to its poor central bioavailability.

For those who remain uncertain, a practical approach is to begin with Citicoline at 250 mg per day for standalone use, or Alpha-GPC at 300 mg per racetam dose for stacking protocols. Doses can be adjusted based on subjective response and any side effects. Some experienced researchers employ both compounds simultaneously. Alpha-GPC for its direct cholinergic support and Citicoline for its uridine-mediated neuroprotection. While this approach lacks formal clinical validation, the mechanistic rationale is sound.

Browse Nootropics at Elite Bio Supply

13. Frequently Asked Questions

What are cholinergic nootropics?

Cholinergic nootropics are compounds that enhance cognitive function by supporting the acetylcholine neurotransmitter system. They work by increasing acetylcholine synthesis (Alpha-GPC, Citicoline), inhibiting acetylcholine breakdown (huperzine A), or enhancing acetylcholine receptor sensitivity (racetams). The choline-based compounds discussed in this article are the most widely used category.

Is Alpha-GPC or Citicoline better for cognitive enhancement?

Neither compound is categorically superior. Alpha-GPC delivers more choline per gram (40% vs 18%) and may be more effective for directly boosting acetylcholine levels. Citicoline provides the additional benefit of uridine, which supports membrane synthesis and synaptic plasticity. The optimal choice depends on the specific goals of the protocol. See our Alpha-GPC guide and CDP-Choline guide for detailed comparisons.

Why do racetams cause headaches without choline?

Racetams increase the rate of acetylcholine turnover in the brain. When choline supply is insufficient to sustain this increased demand, presynaptic acetylcholine stores become depleted. The resulting cholinergic deficit is widely believed to cause the headaches commonly reported by racetam users who do not co-administer a choline source. For more information on this interaction, see our article on piracetam research and safety.

How much choline should researchers take with piracetam?

Community consensus suggests approximately 300 mg of Alpha-GPC or 250 mg of Citicoline per 1600 mg dose of piracetam. These ratios are based on practical experience rather than randomised controlled trials. Individual needs may vary based on dietary choline intake, genetics, and the specific racetam used.

Can choline supplementation cause depression?

In susceptible individuals, excessive cholinergic activity has been associated with depressive symptoms. The cholinergic-adrenergic hypothesis of mood disorders proposes that an imbalance favouring acetylcholine over noradrenaline may contribute to depressive states. Researchers with a history of depression should begin at low doses and monitor mood carefully.

Is choline bitartrate effective for cognitive enhancement?

Choline bitartrate is effective for raising peripheral choline levels and supporting liver health. However, it has poor blood-brain barrier penetration, meaning it is unlikely to significantly increase central acetylcholine synthesis. For cognitive enhancement protocols, Alpha-GPC or Citicoline are strongly preferred.

What is the tolerable upper intake level for choline?

The tolerable upper intake level (UL) for choline is 3500 mg per day for adults, set by the Institute of Medicine. Intake above this level may produce side effects including fishy body odour, gastrointestinal distress, hypotension, and hepatotoxicity. Most cognitive enhancement protocols use choline doses well below this threshold.

Does Citicoline increase dopamine levels?

There is evidence that Citicoline modestly increases dopamine levels in certain brain regions, likely through its role in supporting dopamine receptor membrane integrity and phospholipid synthesis. This dopaminergic activity distinguishes Citicoline from Alpha-GPC and may contribute to its effects on motivation and attention, though the magnitude of this effect at standard doses is modest.

Are cholinergic nootropics safe for long-term use?

Clinical trials of both Alpha-GPC and Citicoline lasting up to 12 months have not identified significant safety concerns at standard doses. Long-term population-level safety data is limited, as is the case with most nootropic compounds. Researchers should periodically reassess their protocols and consult healthcare professionals regarding extended use.

Can choline supplements replace acetylcholinesterase inhibitors?

No. Choline supplements and acetylcholinesterase inhibitors work through fundamentally different mechanisms. Choline supplements increase the substrate available for acetylcholine synthesis, while acetylcholinesterase inhibitors slow the degradation of existing acetylcholine. In clinical Alzheimer’s treatment, the two approaches are not interchangeable, though they are sometimes used concurrently under medical supervision.

14. References

1. Hasselmo ME. The role of acetylcholine in learning and memory. Curr Opin Neurobiol. 2006;16(6):710-715. doi:10.1016/j.conb.2006.09.002
2. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-glycerylphosphoryl-choline) an old choline-containing phospholipid with a still interesting profile as cognition enhancing agent. Funct Neurol. 2013;28(4):241-250.
3. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. Methods Find Exp Clin Pharmacol. 2006;28 Suppl B:1-56.
4. Zeisel SH. Choline: critical role during fetal development and dietary requirements in adults. Annu Rev Nutr. 2006;26:229-250. doi:10.1146/annurev.nutr.26.061505.111156
5. Parker AG, Byars A, Purpura M, Jager R. The effects of alpha-glycerylphosphorylcholine, caffeine or placebo on markers of mood, cognitive function, power, speed, and agility. J Int Soc Sports Nutr. 2015;12(Suppl 1):P41. doi:10.1186/1550-2783-12-S1-P41
6. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. 2005;(2):CD000269. doi:10.1002/14651858.CD000269.pub3
7. Sarter M, Hasselmo ME, Bruno JP, Givens B. Unravelling the attentional functions of cortical cholinergic inputs: interactions between signal-driven and cognitive modulation of signal detection. Brain Res Rev. 2005;48(1):98-111. doi:10.1016/j.brainresrev.2004.08.006
8. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137-147. doi:10.1136/jnnp.66.2.137
9. Davalos A, Castillo J, Alvarez-Sabin J, et al. Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke. 2002;33(12):2850-2857. doi:10.1161/01.STR.0000038691.03334.71
10. Poly C, Massaro JM, Seshadri S, et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. Am J Clin Nutr. 2011;94(6):1584-1591. doi:10.3945/ajcn.110.008938
11. Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci. 2007;257(1-2):264-269. doi:10.1016/j.jns.2007.01.043
12. Conant R, Bhatt DL. CDP-Choline (citicoline) in stroke and TBI: pharmacological basis and clinical evidence. Expert Rev Neurother. 2011;11(4 Suppl):1-5.
13. De Jesus Moreno Moreno M. Cognitive improvement in mild to moderate Alzheimer’s dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial. Clin Ther. 2003;25(1):178-193. doi:10.1016/S0149-2918(03)90023-3
14. Ceda GP, Ceresini G, Denti L, et al. Alpha-glycerylphosphorylcholine administration increases the GH responses to GHRH of young and elderly subjects. Horm Metab Res. 1992;24(3):119-121. doi:10.1055/s-2007-1003272
15. Silveri MM, Dikan J, Ross AJ, et al. Citicoline enhances frontal lobe bioenergetics as measured by phosphorus magnetic resonance spectroscopy. NMR Biomed. 2008;21(10):1066-1075. doi:10.1002/nbm.1281
16. Wallace TC, Fulgoni VL 3rd. Usual choline intakes are associated with egg and protein food consumption in the United States. Nutrients. 2017;9(8):839. doi:10.3390/nu9080839

Canadian researchers can order cholinergic compounds from Elite Bio Supply with fast domestic shipping to Toronto, Vancouver, Montreal, Calgary, and every city across Canada.